Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Hoth Therapeutics Inc
Healthcare
P/NCAV
0.47x
Ticker
HOTH
Exchange
NASDAQ
Country
United States
Close
1.19 $
Mkt Cap
4.1M $
EV
-5.2M $
NCAV Burn Rate
-71.4%
Current Ratio
13.89
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.7x
EV/FCF
0.6x
Dilution
44.3% p.A
Total Net Income
-52.9M $
Cheapness
100.0%
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average